← Leaderboards
Guy L Reed
Harvard University (Sch Of Public Hlth)
$21,498,902
Attributed
$40,006,046
Total exposure
17
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,006,046 · 17
By mechanism
R44$12,438,024 · 5
R01$8,511,629 · 5
UH3$8,271,650 · 1
UG3$5,110,320 · 1
U44$3,299,979 · 1
R42$1,519,440 · 1
Top collaborators
- Sun Yong Jeong7 shared
- Paul H Kussie4 shared
- Jordan J. Elm3 shared
- Pooja Khatri3 shared
- Eva Mistry3 shared
- Andrew H Kang2 shared
- Victor F. Tapson2 shared
- Dong Wang2 shared
Others in their field
Top investigators on “Thrombosis”
- Paul M. Ridker · Brigham And Women'S Hospital$59,264,235
- John H Griffin · Scripps Research Institute$29,245,116
- David J. Pinsky · University Of Michigan At Ann Arbor$29,054,903
- Bruce Furie · Beth Israel Deaconess Medical Center$28,093,838
- Denisa D Wagner · Boston Children'S Hospital$24,247,974
- Satya P. Kunapuli · Temple University$22,403,131
Research focus
ThrombosisCessation Of LifeHemorrhageBlood CoagulationDisabilityStrokeThrombusIschemic StrokePlasminogen ActivatorFibrinolysisEffective TherapyAcuteBrainMonoclonal AntibodiesAntiplasminDoseAlteplasePreventBlood FlowLeadBlood VesselsSafetyMediatingHealth Care Costs
Grant awards (49)
Strategy for Improving Stroke Treatment Response (SISTER) Trial$4,963,344
UH3 · FY2025 · NS
Strategy for Improving Stroke Treatment Response (SISTER) Trial$3,308,306
UH3 · FY2024 · NS
Strategy for Improving Stroke Treatment Response (SISTER) Trial$5,110,320
UG3 · FY2023 · NS
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$1,283,035
R44 · FY2023 · HL
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial$1,408,690
R44 · FY2022 · HL
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$1,161,162
R44 · FY2022 · HL
Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke$1,713,006
R44 · FY2021 · NS
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial$1,408,991
R44 · FY2021 · HL
Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke$1,646,140
R44 · FY2020 · NS
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$1,067,767
R44 · FY2020 · HL
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$1,321,017
R44 · FY2019 · HL
Alpha-2-antiplasmin and Ischemic Stroke$376,975
R01 · FY2019 · NS · contact PI
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$336,200
R41 · FY2019 · HL
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$423,216
R44 · FY2018 · HL · contact PI
Alpha-2-antiplasmin and Ischemic Stroke$376,975
R01 · FY2018 · NS · contact PI
Alpha-2-antiplasmin and Ischemic Stroke$376,975
R01 · FY2017 · NS · contact PI
HLS Potent, novel inhibitor of fibrinolytic hemorrhage$351,119
R43 · FY2017 · HL
Alpha-2-antiplasmin and Ischemic Stroke$376,975
R01 · FY2016 · NS · contact PI
Novel Methods for Dissolving Blood Clots$1,000,000
R44 · FY2015 · HL
Alpha-2-antiplasmin and Ischemic Stroke$376,975
R01 · FY2015 · NS · contact PI
Novel Methods for Dissolving Blood Clots$5,000
R44 · FY2015 · HL
Reducing Stroke by a Novel, Clot-dissolving Antibody$999,993
U44 · FY2014 · NS · contact PI
Reducing Stroke by a Novel, Clot-dissolving Antibody$999,993
U44 · FY2013 · NS
Novel Methods for Dissolving Blood Clots$735,404
R42 · FY2013 · HL · contact PI
Reducing Stroke by a Novel, Clot-dissolving Antibody$999,993
U44 · FY2012 · NS
Novel Methods for Dissolving Blood Clots$784,036
R42 · FY2012 · HL · contact PI
Plasminogen Activation & SK: Structure-Function$293,040
R01 · FY2012 · HL · contact PI
Reducing Stroke by a Novel, Clot-dissolving Antibody$300,000
U44 · FY2011 · NS
Plasminogen Activation & SK: Structure-Function$296,000
R01 · FY2011 · HL · contact PI
Plasminogen Activation & SK: Structure-Function$296,000
R01 · FY2010 · HL · contact PI
Novel Methods for Dissolving Blood Clots$167,685
R41 · FY2010 · HL · contact PI
Plasminogen Activation & SK: Structure-Function$295,667
R01 · FY2009 · HL · contact PI
Secretion in Vascular Inflammation and Thrombosis$271,179
R01 · FY2007 · HL · contact PI
Secretion in Vascular Inflammation and Thrombosis$279,279
R01 · FY2006 · HL · contact PI
Secretion in Vascular Inflammation and Thrombosis$286,000
R01 · FY2005 · HL
Plasminogen Activation &SK: Structure-Function$286,000
R01 · FY2005 · HL
Plasminogen Activation &SK: Structure-Function$323,600
R01 · FY2004 · HL
Secretion in Vascular Inflammation and Thrombosis$286,000
R01 · FY2004 · HL
Plasminogen Activation &SK: Structure-Function$323,600
R01 · FY2003 · HL
PLATELET SECRETION--MOLECULAR AND REGULATION$322,309
R01 · FY2003 · HL
PLATELET SECRETION--MOLECULAR AND REGULATION$58,043
R01 · FY2003 · HL
PLATELET SECRETION--MOLECULAR AND REGULATION$369,274
R01 · FY2002 · HL
MECHANISMS OF DILATED CARDIOMYOPATHY IN CREB A133$364,500
R01 · FY2002 · HL
Plasminogen Activation &SK: Structure-Function$323,600
R01 · FY2002 · HL
PLASMINOGEN ACTIVATION &SK: STRUCTURE - FUNCTION$449,009
R01 · FY2001 · HL
PLATELET SECRETION--MOLECULAR AND REGULATION$367,989
R01 · FY2001 · HL
MECHANISMS OF DILATED CARDIOMYOPATHY IN CREB A133$364,125
R01 · FY2001 · HL
PLASMINOGEN ACTIVATION &SK: STRUCTURE - FUNCTION$423,062
R01 · FY2000 · HL
PLATELET SECRETION--MOLECULAR AND REGULATION$348,478
R01 · FY2000 · HL